---

title: “What EU Article 9.1 Really Costs When Pharma and Cosmetics Fund 80% of Upgrades: A Shanghai ChiMay CFO Read”
date: 2026-07-16
perspective: C-Level Decision Maker
theme: Advanced Oxidation & Micropollutant Removal

---

What EU Article 9.1 Really Costs When Pharma and Cosmetics Fund 80% of Upgrades: A Shanghai ChiMay CFO Read

The Short Version

• Article 9.1 of the recast EU Urban Wastewater Treatment Directive (Directive 2024/3019, in force January 1, 2025) obliges pharmaceutical and cosmetics producers to fund at least 80% of the capital and operating cost of quaternary treatment upgrades through Extended Producer Responsibility (EPR) schemes.
• Independent legal and technical analyses in 2026 estimate EU-wide capex to meet the 2039 quaternary treatment deadline for plants serving 150,000+ people at EUR 3.5-5.0 billion, with an additional annual operating cost in the EUR 800 million range.
• The 80% pharma and cosmetics share is not evenly distributed: high-volume generic manufacturers and consumer cosmetics brands face proportionally larger contributions than niche prescription or luxury cosmetic segments.
• CFOs of affected producers should model both the direct EPR contribution and the indirect cost of documentation, verification, and sensor-based evidence that regulators will increasingly require.

Understanding the Article 9.1 Cost Envelope

Article 9.1 codifies the polluter-pays principle for micropollutant treatment. It transfers the majority of quaternary treatment capex and opex from utility ratepayers to the producers whose products enter wastewater as pharmaceutical residues and cosmetic ingredients. The 80% share is a floor, not a ceiling: member states can push the producer contribution higher.

The cost envelope has three main components:

• Capex contribution: funding new ozone contactors, UV/H2O2 skids, PAC adsorbers, and associated instrumentation across affected wastewater treatment plants.
• Opex contribution: ongoing costs for energy, reagents, sludge handling, and instrumentation maintenance.
• Compliance overhead: documentation, third-party verification, and legal defense costs when methodology or allocation is challenged.

For a mid-sized pharmaceutical producer with EU revenue of EUR 500 million, industry-wide modeling suggests the annual EPR contribution will land somewhere between EUR 5 million and EUR 15 million, depending on product mix and reference concentration data.

Why the 80% Share Is Not Distributed Evenly

The EPR scheme allocates cost by measured or estimated substance contribution to influent, not by revenue. That means:

• Producers of high-volume analgesics, contrast media, and psychiatric medications typically face the highest per-euro-of-revenue EPR burden.
• Cosmetics producers with high-volume consumer products containing UV filters and preservatives that are difficult to biodegrade face similarly high burdens.
• Niche prescription drugs with low environmental persistence face lower burdens.
• Cosmetics with fully biodegradable ingredient profiles face lower burdens.

Producers that invest in reformulation toward more biodegradable actives can materially reduce their EPR liability over the medium term. The reformulation return on investment belongs in the CFO’s Article 9.1 modeling.

Modelling the Direct Contribution

A CFO modeling Article 9.1 exposure should build three scenarios:

• Baseline: the producer contributes proportionally to its measured or estimated influent share, with EPR paid annually to member state schemes.
• Reformulation scenario: the producer accelerates reformulation of high-EPR-cost products, reducing exposure by 20-40% over five years.
• Advocacy scenario: the producer engages industry associations to influence measurement methodology and allocation rules, potentially reducing exposure by 5-15% depending on jurisdiction.

Each scenario carries its own documentation and verification cost, and each carries a different risk of regulatory challenge. The CFO’s job is to price all three and make an informed capital allocation decision.

The Documentation and Verification Cost

Beyond the direct EPR payment, Article 9.1 will generate a substantial documentation cost. Utilities will need:

• Continuous influent load monitoring to allocate cost fairly across contributing producers.
• Continuous treatment efficiency reporting to demonstrate that funded upgrades actually achieve their design pollutant removal.
• Third-party verification of both influent load and treatment efficiency.
• Sensor-based evidence that survives regulatory audit and legal challenge.

For producers, this means their EPR contribution funds not only the ozone contactor or PAC adsorber, but also the continuous instrumentation and reporting infrastructure that documents utility performance. Producers who understand this documentation layer can negotiate their contribution more effectively.

The Sensor Layer Behind the Cost

Every quaternary treatment plant funded under Article 9.1 will carry an instrumentation package broadly comprising:

• Multi-parameter sensors on influent, contactor, and effluent for compliance-grade measurement.
• In-line pH electrodes on ozone contactors and PAC adsorbers to document dosing chemistry.
• Residual chlorine transmitters, configurable for ozone or peroxide service, to document terminal residuals.
• Online turbidity testers on advanced oxidation feed water to document upstream water quality.
• Conductivity analyzers for byproduct trending.
• Suspended solids sensors and COD sensors on PAC lines.

Sensor cost is a small share of total upgrade capex, typically 3-6% — but the sensor layer produces the evidence that determines whether the utility can invoice the producer for the full 80%. Producers should therefore prefer utility partners that specify continuous, drift-managed analyzers with published Modbus register maps and documented calibration protocols.

Board-Level Questions for the CFO

CFOs briefing the board on Article 9.1 exposure should be ready to answer:

• What is our current best estimate of annual EPR contribution across each EU member state?
• How is that estimate expected to evolve as more plants come under the 2039 deadline?
• What is our reformulation pipeline and its expected impact on EPR exposure?
• What is our exposure to methodology change through legal challenge or advocacy?
• How confident are we in the utility partners funding our upgrade contributions, and in the sensor-based evidence they produce?

These questions are not academic. Multiple 2026 legal analyses reference ongoing challenges to Article 9.1 methodology, and the outcome will materially affect producer exposure across the next decade.

Strategic Response Options

Beyond financial modeling, CFOs have several strategic response levers:

• Engagement: support industry associations working on measurement methodology and allocation rules.
• Reformulation: invest in R&D toward more biodegradable actives to reduce medium-term EPR exposure.
• Partnership: co-fund quaternary treatment installations at key utility partners in exchange for reporting transparency and cost containment.
• Transparency: disclose Article 9.1 exposure and management strategy in annual sustainability reports, which increasingly influence investor and lender behavior.
• Instrumentation influence: encourage utility partners to standardize on continuous, drift-managed analyzers so EPR invoicing is defensible and auditable.

Bottom Line

Article 9.1 is one of the most operationally significant regulatory changes affecting European pharmaceutical and cosmetics producers this decade. The 80% cost share is not an abstract policy detail; it is a line item that will show up in quarterly financial statements for years to come. Shanghai ChiMay’s residual chlorine transmitter, in-line pH electrode, multi-parameter sensor, and online turbidity tester families sit at the sensor layer of every Article 9.1-funded quaternary treatment upgrade, giving producers and utilities alike the drift-managed, audit-ready measurement stack that makes EPR allocation defensible and cost containment realistic.